Atovaquone

阿托伐醌

Report date: 2026/04/06 20:01:48
NME

Base Information

Drug NameAtovaquone
Drug Alias NameWellvole阿托喹酮阿托夸酮atovaquonum阿扎伐醌 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome b inhibitors
TargetsCytochrome b
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diffuse midline gliomaCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsPneumonia, Pneumocystis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1992/11/25
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesHetero Labs LtdUniversity Of OxfordEmory University +[4] 
Inactive CompaniesUniversity of Texas Southwestern Medical CenterGlaxo Wellcome IncGlaxosmithkline Plc +[5] 
Active IndicationsDiffuse midline gliomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HIV InfectionsMalaria

Other Information

ATC CodeP01AX06
Related LinksWikipediaDrugBankKEGG